¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"spur cell anemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • hypersensitized cell
    °ú¹Î°¨¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò¼¼Æ÷¹Î°¨Á¦
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • hair cell
    Åм¼Æ÷
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper cell
    µµ¿ò¼¼Æ÷, Á¶·Â¼¼Æ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä, Ç÷±¸Çü¼º¼¼Æ÷À̽Ä
  • hairy cell
    Åиð¾ç¼¼Æ÷
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • islet cell
    ¼¶¼¼Æ÷
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
  • juvenile cell
    À¯¾à¼¼Æ÷
  • killer cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • Kupffer¡¯s cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • lacunar cell
    °ø°£¼¼Æ÷
  • large cell carcinoma
    Å«¼¼Æ÷¾ÏÁ¾, ´ë¼¼Æ÷¾ÏÁ¾
  • lepra cell
    ³ªº´¼¼Æ÷
  • leukemic cell
    ¹éÇ÷º´¼¼Æ÷
  • light cell
    ¹àÀº¼¼Æ÷
  • lipoid cell
    ÁöÁú¼¼Æ÷
  • luteal cell
    Ȳü¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º¼¼Æ÷µ¶¼º¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸»ý¼º¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç.(¡­ðþåË)
  • giant cell, langhans
    ¶ûÇѽº °Å´ë¼¼Æ÷, Langhans °Å´ë¼¼Æ÷
  • giant pyramidal cell
    Å«ÇǶó¹Ô½Å°æ¿ø, °Å´ëÃßü¼¼Æ÷(¡­õÐô÷á¬øà).
  • gingiva,giant cell granuloma of
    °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • glandular cell
    »ù¼¼Æ÷, ¼±¼¼Æ÷(àÍá¬øà).
  • glandular cell
    »ù¼¼Æ÷
  • glassy cell carcinoma of cervix
    À¯¸®¾ç ¼¼Æ÷ ÀڱðæºÎ¾Ï
  • glia cell
    ¾Æ±³¼¼Æ÷, (½Å°æ)±³¼¼Æ÷.
  • gliacyte =glia cell
    ¾Æa¼¼Æ÷, (½Å°æ)a¼¼Æ÷(¡­á¬øà).
  • gliacyte =glia cell
    ¾Æ±³¼¼Æ÷, (½Å°æ)±³¼¼Æ÷(¡­á¬øà).
  • glial cell
    ¾Æa¼¼Æ÷, (½Å°æ)a¼¼Æ÷.
  • glial cell
    ¾Æ±³¼¼Æ÷
  • glial cell body
    ¾Æ±³¼¼Æ÷ü
  • glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
  • glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
  • refractory anemia relapsing polychondroritis
  • refractory anemia with excess blast =RAEB
    ¸ð¼¼Æ÷°ú´ÙºÒÀÀ¼ººóÇ÷
  • refractory anemia with excess blasts
    ¸ð¼¼Æ÷°ú´Ù¼º ºÒÀÀ¼ººóÇ÷
  • refractory anemia with ring sideroblast
    ȯ»óöÀû¸ð±¸(ü»ßÒôÑîåٽϹ)¼º ºÒÀÀ¼ººóÇ÷
  • refractory megaloblastic anemia
    Ç×Ä¡·á¼º°ÅÀû¾Æ±¸ºóÇ÷(ùñö½èþàõËÝîåä´Ï¹Þ¸ úì).
  • refractory megaloblastic anemia
    Ç×Ä¡·á¼º°ÅÀû¾Æ±¸ºóÇ÷(ùñö½èþàõËÝîåä´Ï¹Þ¸úì)
  • refractory sideroblastic anemia
    ºÒÀÀ¼ºÃ¶Àû¸ð±¸ºóÇ÷
  • scorbutic anemia
    ±«Ç÷º´¼º ºóÇ÷(¡­Þ¸úì).
  • scorbutic anemia
    ±«Ç÷º´¼º ºóÇ÷(ÎÕúìÜ»àõÞ¸úì)
  • secondary anemia
    ¼Ó¹ß¼º ºóÇ÷(áÙÛ¡àõ Þ¸úì).
  • secondary anemia
    ¼Ó¹ß¼º ºóÇ÷(áÙÛ¡àõ Þ¸úì)
  • secondary hemolytic anemia
    ¼Ó¹ß¼º ¿ëÇ÷¼º ºóÇ÷(áÙÛ¡àõéÁúìàõÞ¸úì).
  • secondary hemolytic anemia
    ¼Ó¹ß¼º ¿ëÇ÷¼º ºóÇ÷(áÙÛ¡àõéÁúìàõÞ¸úì)
  • sideroblastic anemia
    öÀû¸ð±¸¼º ºóÇ÷
  • sideroblastic anemia
    öÀû¸ð±¸¼º ºóÇ÷.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
MAHA microangiopathic hemolytic anemia
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
MHA major histocompatibility antigen; May-Hegglin anomaly; Mental Health Association; methemalbumin; mic...
PASA para-aminosalicylic acid; primary acquired sideroblastic anemia; proximal articular set angle
PDA patent ductus arteriosus; personal digital assistant; posterior descending artery; pulmonary disease...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 17
LCL B-lymphoblastoid cell line
LCL lymphoblastoid cell
LCL B-lymphoid cell lines
BCC Basal Cell Carcinoma
BCNS Basal Cell Nevus Syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • lupus erythematosus cell
    È«¹Ý¼º ·çǪ½º ¼¼Æ÷, È«¹Ý¼º ³¶Ã¢ ¼¼Æ÷
  • M-cell
    M ¼¼Æ÷
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
  • mast cell
    ºñ¸¸ ¼¼Æ÷
    µ¿¹°ÀÇ °áÇÕ Á¶Á÷ ¼Ó¿¡ ÀÖ´Â ¼¼Æ÷·Î ¸¸¼º ¿°Áõ¿¡ À־ÀÇ Áõ½Ä Á¶Á÷ ¼Ó¿¡ ¸¹¾Æ¼­ ÀÌ·± À̸§ÀÌ ºÙ¾ú´Ù. ÀÌ ¼¼Æ÷ ¼Ó¿¡´Â ¸¹Àº °ú¸³ÀÌ µé¾îÀÖ¾î ¿°Áõ ¹ÝÀÀ¿¡ °ü¿©Çϰí ÀÖ´Ù.
  • mature daughter cell
    ¼º¼÷ÇÑ µþ ¼¼Æ÷
  • mean cell

    mean cell hemoglobin (Æò±Õ ÀûÇ÷±¸ Ç÷»ö¼Ò

  • mean cell volume
    Æò±Õ ÀûÇ÷±¸ ¿ëÀû
  • megakaryocytic blast cell
    °ÅÇÙ¸ð±¸
  • memory T cell
    ±â¾ï T ¼¼Æ÷
    Ç׿øÀÌ µé¾î¿ÔÀ» ¶§ B ¼¼Æ÷°¡ Èä¼±À» ÀÚ±ØÇÏ¿© T ¸²ÇÁ±¸¸¦ »ý»ê, ºÐÈ­ÇÒ ¶§ Ç׿ø-Ç×ü ¹ÝÀÀÀ» ÇÏÁö ¾Ê°í ³²¾Æ ±× Ç׿øÀ» ±â¾ïÇÏ¿© 2Â÷ Ç׿ø-Ç×ü ¹ÝÀÀ¿¡ ½Å¼ÓÈ÷ ¹ÝÀÀÀ» º¸À̵µ·Ï ÇÏ´Â T ¼¼Æ÷.
  • Merkel's cell
    Ã˰¢ ¼¼Æ÷
    µ¿ÀǾî=tactile e
  • mesenchymal cell
    °£¿± ¼¼Æ÷, Áß°£¿± ¼¼Æ÷
    ¼ºÀÎ À¯±âü¿¡ ÀÜÁ¸ ½Ã¿¡´Â ¼¼Æ÷µéÀº º¸Åë ÀÛÀº Ç÷°üÀ» µû¶ó ¼Ò¼º °áüÁ¶Á÷À̳ª ¸Á»ó ¼¶À¯ ³»¿¡ Á¤·ÄÇØ ÀÖ´Ù. À̵éÀº À§Ä¡³ª ´Ù¸¥ Á¾·ùÀÇ ¼¼Æ÷
  • mixed germ cell tumors
    È¥ÇÕ ¹è¾Æ¼¼Æ÷ Á¾¾ç
  • mixed small and large cell lymphoma
    È¥ÇÕ¼º ´ë¼Ò¼¼Æ÷ ¸²ÇÁÁ¾
  • monkey kidney cell
    ¿ø¼þÀÌ ½Å¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 17
renal cell carcinoma <oncology, tumour> The most common form of kidney cancer which occurs when the cells lining the renal tubule undergo cancerous changes. There are approximately 18,000 new cases of renal cell carcinoma (hypernephroma) per year in the U.S. With about 8,000 deaths annually.
Smoking is considered a major risk factor. Kidney dialysis patients are at increased risk for the development of hypernephroma. Family history for renal cell carcinoma is also considered a risk factor.
Symptoms include haematuria, flank pain, abdominal pain, back pain, weight loss and abdominal swelling.
(27 Sep 1997)
cell bridges Slender cytoplasmic strands connecting adjacent cells; in histological sections of the epidermis and other stratified squamous epithelia, the bridge's are processes attached by a desmosome and are shrinkage artifacts of fixation; true bridge's with cytoplasmic confluence exist between incompletely divided germ cells.
Synonym: cell bridges, cytoplasmic bridges.
(05 Mar 2000)
cell centre Microtubule organising centre of the cell, the pericentriolar region.
(18 Nov 1997)
cell cloning The process of producing a group of cells (clones), all genetically identical, from a single ancestral cell.
(12 Dec 1998)
cell communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP.
(12 Dec 1998)
cell compartmentation A partitioning within cells due to the selectively permeable membranes which enclose each of the separate parts, e.g., mitochondria, lysosomes, etc.
(12 Dec 1998)
cell count A count of the number of cells of a specific kind, usually measured per unit volume of sample.
(12 Dec 1998)
cell culture General term referring to the maintenance of cell strains or lines in the laboratory.
(18 Nov 1997)
cell cycle <cell biology, molecular biology> The sequence of events between mitotic divisions. The cycle is conventionally divided into G0, G1, (G standing for gap), S (synthesis phase during which the DNA is replicated), G2 and M (mitosis).
Cells that will not divide again are considered to be in G0 and the transition from G0 to G1 is thought to commit the cell to completing the cycle and dividing.
(26 Mar 1998)
cell cycle proteins Proteins that control the cell division cycle. This family of proteins includes a wide variety of classes, including cyclin-dependent kinases, mitogen-activated kinases, cyclins, and phosphoprotein phosphatases (phosphoprotein phosphatase) as well as their putative substrates such as chromatin-associated proteins, cytoskeletal proteins, and transcription factors.
(12 Dec 1998)
cell cycle restriction point <cell biology, molecular biology> A point, late in G1, after which the cell must, normally, proceed through to division at its standard rate.
(26 Mar 1998)
cell death <cell biology> Cells die (nonaccidentally) either when they have completed a fixed number of division cycles (around 60, the Hayflick limit) or at some earlier stage when programmed to do so, as in digit separation in vertebrate limb morphogenesis.
Whether this is due to an accumulation of errors or a programmed limit is unclear, some transformed cells have undoubtedly escaped the limit.
See: apoptosis.
(26 Mar 1998)
cell degranulation The process of losing cytoplasmic granules. This occurs in mast cells, basophils, neutrophils, eosinophils, and platelets when secretory products are released from the granules.
(12 Dec 1998)
cell determination The process by which embryonic cells, previously undifferentiated, take on a specific developmental character.
Although the mechanism is not fully understood, homeotic proteins coded for by certain gene sequences (the homeobox) appear to trigger the process. Genes for homeotic proteins show remarkable similarity among species.
See: morphogenesis, induction, evocator.
(05 Mar 2000)
cell differentiation Progressive restriction of the developmental potential and increasing specialization of function which takes place during the development of the embryo and leads to the formation of specialised cells, tissues, and organs.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 17
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 17
ÅëÇÕ°Ë»ö ¿Ï·á